# SciSparc Ltd. (SPRC)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Price:** $8.66 (-6.98%)

> SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on developing cannabinoid-based therapies for central nervous system disorders. Its primary drug development programs include SCI-110, targeting Tourette syndrome, Alzheimer’s disease and agitation, and obstructive sleep apnea, and SCI-110 for autism spectrum disorder and status epilepticus, conducted through its majority-owned subsidiary NeuroThera Labs Inc. The company also advances intellectual property in areas such as opioid-N-acylethanolamine combinations for pain management, neuroplastogen therapies, and the MUSE system, an endoscopic device for gastroesophageal reflux disease treatment. Additionally, SciSparc sells hemp seed oil-based nutraceutical products, including gummies, oil capsules, creams, and beauty treatments, via online marketplaces. It pursues innovative initiatives like quantum computing-enabled 3D protein modeling to enhance AI-driven drug discovery for neurological conditions. Founded in 2004 and headquartered in Tel Aviv, Israel, SciSparc operates in the pharmaceuticals and biotech sectors, emphasizing cannabinoid technologies and related IP assets.

Financial data not yet available for this company.

Source: [CompaniesByCap](https://companiesbycap.com/company/SPRC)